Aytu Bioscience Stock EBITDA

AYTU Stock

USD 1.63 0.12 7.95%

Aytu BioScience fundamentals help investors to digest information that contributes to Aytu BioScience's financial success or failures. It also enables traders to predict the movement of Aytu Stock. The fundamental analysis module provides a way to measure Aytu BioScience's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aytu BioScience stock.

		Last Reported	Projected for Next Year
	EBITDA	-1 M	-1.1 M

EBITDA is likely to drop to about (1.1 M) in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Aytu BioScience Company EBITDA Analysis

Aytu BioScience's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Aytu BioScience EBITDA

(1.01 M)

Most of Aytu BioScience's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aytu BioScience is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Aytu EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for Aytu BioScience is extremely important. It helps to project a fair market value of Aytu Stock properly, considering its historical fundamentals such as EBITDA. Since Aytu BioScience's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Aytu BioScience's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Aytu BioScience's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Net Tangible Assets	Current Deferred Revenue	Capital Surpluse	Intangible Assets	Property Plant Equipment	Net Receivables	Good Will	Deferred Long Term Liab	Long Term Debt	Short Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock	Long Term Debt Total
Total Assets		0.92	-0.56	-0.72	0.97	0.95	0.98	0.67	-0.43	-0.26	0.83	0.86	0.96	0.87	0.85	0.83	-0.68	0.33	-0.63	0.57	0.97	0.18	0.3	-0.25
Total Stockholder Equity	0.92		-0.74	-0.41	0.89	0.74	0.87	0.74	-0.35	0.06	0.6	0.64	0.84	0.68	0.59	0.55	-0.52	0.13	-0.48	0.65	0.97	0.35	0.53	0.03
Net Debt	-0.56	-0.74		0.13	-0.55	-0.34	-0.56	-0.27	0.3	-0.56	-0.04	-0.44	-0.44	-0.1	-0.13	-0.19	0.42	-0.19	0.38	-0.15	-0.63	-0.85	-0.85	-0.09
Retained Earnings	-0.72	-0.41	0.13		-0.72	-0.89	-0.8	-0.17	0.49	0.61	-0.84	-0.93	-0.81	-0.78	-0.92	-0.96	0.78	-0.7	0.74	-0.04	-0.57	0.03	0.07	0.58
Accounts Payable	0.97	0.89	-0.55	-0.72		0.92	0.96	0.61	-0.44	-0.27	0.84	0.83	0.97	0.83	0.84	0.78	-0.69	0.38	-0.63	0.49	0.92	0.19	0.31	-0.09
Total Liab	0.95	0.74	-0.34	-0.89	0.92		0.96	0.54	-0.45	-0.5	0.92	0.93	0.95	0.93	0.97	0.96	-0.74	0.46	-0.68	0.43	0.86	0.02	0.08	-0.43
Total Current Assets	0.98	0.87	-0.56	-0.8	0.96	0.96		0.56	-0.44	-0.26	0.82	0.91	0.95	0.84	0.89	0.88	-0.71	0.41	-0.66	0.45	0.94	0.24	0.31	-0.33
Short Term Debt	0.67	0.74	-0.27	-0.17	0.61	0.54	0.56		-0.3	-0.2	0.52	0.32	0.58	0.68	0.45	0.35	-0.21	-0.31	-0.16	0.94	0.72	-0.24	-0.01	0.0
Common Stock	-0.43	-0.35	0.3	0.49	-0.44	-0.45	-0.44	-0.3		0.16	-0.32	-0.59	-0.48	-0.34	-0.36	-0.4	0.63	-0.49	0.58	0.01	-0.32	-0.15	-0.09	0.18
Net Tangible Assets	-0.26	0.06	-0.56	0.61	-0.27	-0.5	-0.26	-0.2	0.16		-0.68	-0.36	-0.39	-0.64	-0.63	-0.59	0.37	-0.3	0.34	-0.19	-0.11	0.73	0.72	0.33
Current Deferred Revenue	0.83	0.6	-0.04	-0.84	0.84	0.92	0.82	0.52	-0.32	-0.68		0.76	0.9	0.96	0.95	0.88	-0.58	0.38	-0.54	0.46	0.72	-0.28	-0.13	-0.26
Capital Surpluse	0.86	0.64	-0.44	-0.93	0.83	0.93	0.91	0.32	-0.59	-0.36	0.76		0.88	0.77	0.87	0.93	-0.86	0.67	-0.81	0.15	0.75	0.24	0.21	-0.53
Intangible Assets	0.96	0.84	-0.44	-0.81	0.97	0.95	0.95	0.58	-0.48	-0.39	0.9	0.88		0.9	0.88	0.86	-0.73	0.46	-0.67	0.44	0.89	0.11	0.24	-0.18
Property Plant Equipment	0.87	0.68	-0.1	-0.78	0.83	0.93	0.84	0.68	-0.34	-0.64	0.96	0.77	0.9		0.92	0.87	-0.59	0.27	-0.56	0.62	0.81	-0.29	-0.11	-0.35
Net Receivables	0.85	0.59	-0.13	-0.92	0.84	0.97	0.89	0.45	-0.36	-0.63	0.95	0.87	0.88	0.92		0.96	-0.65	0.44	-0.61	0.38	0.74	-0.16	-0.12	-0.48
Good Will	0.83	0.55	-0.19	-0.96	0.78	0.96	0.88	0.35	-0.4	-0.59	0.88	0.93	0.86	0.87	0.96		-0.72	0.53	-0.68	0.27	0.7	-0.04	-0.04	-0.59
Deferred Long Term Liab	-0.68	-0.52	0.42	0.78	-0.69	-0.74	-0.71	-0.21	0.63	0.37	-0.58	-0.86	-0.73	-0.59	-0.65	-0.72		-0.82	0.97	0.0	-0.59	-0.27	-0.2	0.32
Long Term Debt	0.33	0.13	-0.19	-0.7	0.38	0.46	0.41	-0.31	-0.49	-0.3	0.38	0.67	0.46	0.27	0.44	0.53	-0.82		-0.85	-0.5	0.2	0.32	0.17	-0.22
Short Term Investments	-0.63	-0.48	0.38	0.74	-0.63	-0.68	-0.66	-0.16	0.58	0.34	-0.54	-0.81	-0.67	-0.56	-0.61	-0.68	0.97	-0.85		0.03	-0.56	-0.27	-0.18	0.3
Short Long Term Debt	0.57	0.65	-0.15	-0.04	0.49	0.43	0.45	0.94	0.01	-0.19	0.46	0.15	0.44	0.62	0.38	0.27	0.0	-0.5	0.03		0.65	-0.33	-0.09	0.01
Net Invested Capital	0.97	0.97	-0.63	-0.57	0.92	0.86	0.94	0.72	-0.32	-0.11	0.72	0.75	0.89	0.81	0.74	0.7	-0.59	0.2	-0.56	0.65		0.24	0.4	-0.16
Net Working Capital	0.18	0.35	-0.85	0.03	0.19	0.02	0.24	-0.24	-0.15	0.73	-0.28	0.24	0.11	-0.29	-0.16	-0.04	-0.27	0.32	-0.27	-0.33	0.24		0.89	0.12
Capital Stock	0.3	0.53	-0.85	0.07	0.31	0.08	0.31	-0.01	-0.09	0.72	-0.13	0.21	0.24	-0.11	-0.12	-0.04	-0.2	0.17	-0.18	-0.09	0.4	0.89		0.25
Long Term Debt Total	-0.25	0.03	-0.09	0.58	-0.09	-0.43	-0.33	0.0	0.18	0.33	-0.26	-0.53	-0.18	-0.35	-0.48	-0.59	0.32	-0.22	0.3	0.01	-0.16	0.12	0.25

Click cells to compare fundamentals

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict Aytu BioScience

Ebitda Over Time

Aytu Ebitda

Ebitda

(1.06 Million)

At this time, Aytu BioScience's EBITDA is comparatively stable compared to the past year.

According to the company disclosure, Aytu BioScience reported earnings before interest,tax, depreciation and amortization of (1.01 Million). This is 100.12% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The ebitda for all United States stocks is 100.03% higher than that of the company.

Aytu EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aytu BioScience's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aytu BioScience could also be used in its relative valuation, which is a method of valuing Aytu BioScience by comparing valuation metrics of similar companies.

Aytu BioScience is currently under evaluation in ebitda category among its peers.

Aytu BioScience Institutional Holders

Institutional Holdings refers to the ownership stake in Aytu BioScience that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Aytu BioScience's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Aytu BioScience's value.

		Shares
Morgan Stanley - Brokerage Accounts	2024-06-30	880
Jpmorgan Chase & Co	2024-06-30	540
Ubs Group Ag	2024-06-30	308
Advisor Group Holdings, Inc.	2024-06-30	300
Wells Fargo & Co	2024-06-30	124
Bank Of America Corp	2024-06-30	92.0
Atlantic Trust Group, Llc	2024-06-30	83.0
Group One Trading, Lp	2024-06-30	37.0
Goss Wealth Management Llc	2024-06-30	21.0
Nantahala Capital Management, Llc	2024-09-30	1.1 M
Stonepine Capital Management Llc	2024-06-30	472.5 K

Aytu Fundamentals

	Return On Equity	-0.47
	Return On Asset	-0.0106
	Profit Margin	(0.20) %
	Operating Margin	(0.04) %
	Current Valuation	6.47 M
	Shares Outstanding	6.15 M
	Shares Owned By Insiders	2.43 %
	Shares Owned By Institutions	34.04 %
	Number Of Shares Shorted	192.76 K
	Price To Earning	(0.77) X
	Price To Book	0.34 X
	Price To Sales	0.12 X
	Revenue	81 M
	Gross Profit	66.63 M
	EBITDA	(1.01 M)
	Net Income	(15.84 M)
	Cash And Equivalents	23.81 M
	Cash Per Share	0.38 X
	Total Debt	15.13 M
	Debt To Equity	0.47 %
	Current Ratio	1.02 X
	Book Value Per Share	4.64 X
	Cash Flow From Operations	(1.39 M)
	Short Ratio	10.45 X
	Earnings Per Share	(1.70) X
	Target Price	8.0
	Number Of Employees	102
	Beta	-1.4
	Market Capitalization	10.02 M
	Total Asset	118.09 M
	Retained Earnings	(319.97 M)
	Working Capital	(337 K)
	Current Asset	6.36 M
	Current Liabilities	8.73 M
	Net Asset	118.09 M

About Aytu BioScience Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Aytu BioScience's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aytu BioScience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aytu BioScience based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Aytu Stock Analysis

When running Aytu BioScience's price analysis, check to measure Aytu BioScience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aytu BioScience is operating at the current time. Most of Aytu BioScience's value examination focuses on studying past and present price action to predict the probability of Aytu BioScience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aytu BioScience's price. Additionally, you may evaluate how the addition of Aytu BioScience to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC